NAATs for viral RNA antigen detection
(NP swab, oropharyngeal swab, sputum, bronchoalveolar
lavage fluid, others)
|
Direct detection of SARS-CoV-2 viral RNA
|
High throughput RT-PCR6
|
1.5–8 hours
|
Up to 384
|
>1.23 cp/μL7
450–540,000 NDU/mL8
>90%/up to 100%
|
|
|
Point-of-care RT-PCR |
20 mins |
1 |
>12
cp/mL7
|
|
|
High-throughput TMA |
3 hours |
Unconfirmed |
600
NDU/mL9
|
|
|
Point-of-care LAMP
|
20–60 mins
|
1
|
>10 cp/μl7
>75% sensitivity10
|
|
|
High-throughput LAMP (fluorescence) |
45 mins |
96 |
>1
cp/μl |
|
|
CRISPR/LAMP lateral flow |
15 mins |
1 |
>6.75
cp/μL7
|
Antigen detection |
|
|
|
|
|
(saliva, NP swab) |
Immunoassays for the detection of
SARS-CoV-2 viral antigens |
High-throughput centralized |
From 18 mins |
Up to 300 |
Sensitivity (95% CI) <5 days
post symptom onset and
Ct <30: 97.5%
(92.8–99.5%), Ct >30: 26.7%
(12.3–45.9%)11
|
|
|
Point-of-care (lateral flow)
|
15–30 mins
|
1
|
Sensitivity (95% CI): 28.9% (16.4–44.3) – 98.3% (91.1–99.7)
Specificity (95% CI): 92.4% (87.4– 95.9) –100%
(99.7–100)12
|
Antibody detection
(serum, plasma)
|
Detection of immune response i.e. past exposure to
SARS-CoV-2
|
High-throughput centralized
|
First results from 18 mins to 24 hours
|
Up to 500
|
Typically, >90% sensitive and >95%
specific13
|
|
|
Point-of-care (lateral flow) |
15 mins |
1 |
Typically,
>90% sensitive and >95%
specific13
|